US00901B1052 - Common Stock
AIM IMMUNOTECH INC
NYSEARCA:AIM (5/17/2024, 7:04:00 PM)
After market: 0.4 0 (-0.74%)0.403
+0.01 (+3.33%)
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 22 full-time employees. The firm is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules and Alferon N Injection (Interferon Alfa-N3). Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS) and is an experimental drug in the United States undergoing clinical development for the treatment of certain cancers and ME/CFS. Alferon N Injection is the registered trademark for its injectable formulation of natural alpha interferon. Alferon N Injection is a natural-source, multi-species alpha interferon approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
AIM IMMUNOTECH INC
2117 SW Highway 484
Ocala FLORIDA 34473
P: 13524487797
CEO: Thomas K. Equels
Employees: 22
Website: https://aimimmuno.com/
AIM stock results show that AIM ImmunoTech missed analyst estimates for earnings per share the first quarter of 2024.
Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications Company to...
OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host...
OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully...
Next safety cohort to begin escalated dosing soon...
OCALA, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner...
Here you can normally see the latest stock twits on AIM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: